-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 28, 2022, Tecoro Bio announced that its topical TDM-105795 tincture for patients with androgenetic alopecia (AGA) completed the first clinical phase 1b (MAD) trial in the United States on February 23 last week.
The Phase 1b clinical trial is a 28-day multiple dose escalation study, which is a "randomized, double-blind, vehicle-controlled, parallel group, multiple dose escalation study to evaluate the efficacy of TDM-105795 in patients with androgenic Safety, tolerability and pharmacokinetics in healthy male subjects with alopecia
About TDM-105795
About TDM-105795TDM-105795 is a small molecule drug candidate that is a topical drug that promotes hair growth
About Androgenetic Alopecia (AGA)
About Androgenetic Alopecia (AGA)Androgenetic alopecia (AGA), also known as male or female pattern baldness, is the most common type of hair loss affecting both men and women, with a higher incidence in men
(Original abridged)